Abstract
The selective estrogen receptor modulator, 4-hydroxytamoxifen (4-OHT) is a full agonist at the transforming growth factor (TGF) α gene in ER negative breast cancer cells stably transfected with ERα cDNA (Levenson et al., Br. J. Cancer 77 (1998) 1812-1819). E2 and 4-OHT increase TGFα mRNA and protein in a concentration dependent manner. The responses to E2 and 4-OHT are blocked by the pure antiestrogen ICI 182,780, which does not induce TGFα. Transfected MDA-MB-231 cells contain functional ERα but no ERβ function was detected. Neo transfected cells that did not express ERα or cells stably transfected with the DNA binding domain mutant C202R/E203V which prevents gene activation did not induce TGFα mRNA after either E2 or 4-OHT treatment. An examination of the time course for either 10 nM E2 or 1 μM 4-OHT for MDA-MB-231 cells stably transfected with cDNA for ERα showed increases in TGFα mRNA within 2 or 3 h respectively. Cells pretreated with cycloheximide (1 μg/ml) showed induced TGFα mRNA in response to E2 or 4-OHT but TGFα mRNA induction was blocked by actinomycin D (1 μg/ml). We conclude that both E2 and 4-OHT induce TGFα by direct interaction of ERα with DNA and that ERβ is not involved in the estrogen-like response to 4-OHT in the MDA-MB-231 cells.
Original language | English (US) |
---|---|
Pages (from-to) | 41-50 |
Number of pages | 10 |
Journal | Journal of Steroid Biochemistry and Molecular Biology |
Volume | 78 |
Issue number | 1 |
DOIs | |
State | Published - 2001 |
Externally published | Yes |
Keywords
- Antiestrogen
- Breast cancer
- ER
- TGFα
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Biochemistry
- Molecular Medicine
- Molecular Biology
- Endocrinology
- Clinical Biochemistry
- Cell Biology